Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

atements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Conn. , Aug. 21, 2014  Aptuit ... West Lafayette, Indiana , has enhanced ... and characterization of small and large molecules, including ... of the Bruker maXisPlus Q-TOF mass spectrometer. ... Goldman , CEO, Aptuit, said, "The expanded large ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... Feb. 2, 2012 Venture capital (VC) funding in ... Biotechnology and Medical Device industries, increased 21% during 2011, ... that includes data from the PricewaterhouseCoopers LLP/National Venture ... Reuters .  Venture capitalists invested a total of $7.5 ...
... PARK, Calif., Feb. 2, 2012  BioParadox, Inc., a ... cardiovascular disease, today announced a strategic alliance with ... are delighted to begin working with the Fogarty ... developing creative solutions for patients with challenging problems.  ...
Cached Medicine Technology:Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 2Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 3Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 4BioParadox Announces Partnership with Fogarty Institute for Innovation 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Legal ... system created by Greg Marks has been generating a ... this month. The commotion surrounding the new product has ... investigative review. , “In recent years the ... software systems, commonly referred to as robots or ‘bots,'” ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final ... of ProIntro Vol.3, a customizable title tool for FCPX ... just by dragging ProIntro Vol.3 in their timeline" says Christina ... definite time saver and i think our users will agree" ... designed titles made with Final Cut Pro X users in ...
(Date:8/23/2014)... Teen substance abuse ranks as one of ... NC. Countless adolescents throughout North Carolina struggle with a drug ... never receive professional rehab due to a lack of information ... help. Troubled Teens Holly Springs is a helpline designed to ... teenage alcohol abusers in Wake County who are seeking ...
(Date:8/22/2014)... 2014 On Friday, Aug. 22, Liberty ... Health Sciences , hosting a ceremony in its courtyard ... government and public welfare. , The 162-member inaugural class ... (LUCOM) joined Liberty staff, faculty, and community leaders ... the new medical school. Classes began on Monday, Aug. ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... A-I ratio is not a better predictor of coronary ... total cholesterol and HDL-C, according to a study in ... instruments and guidelines for coronary heart disease (CHD) prevention ... cholesterol, or both for CHD risk assessment. But in ...
... scale, multiethnic study of its kind, researchers at UCLA ... known as cytokines as a cause of Type 2 ... biological markers that may be used to more accurately ... , Reporting in the August 15 issue of the ...
... improve their understanding of the potential increased risk of ... study conducted by researchers from The Childrens Hospital in ... New Haven, CT. , Like many radiology departments around ... exposure to children caused by increased usage of CT. ...
... Columbia University Medical Center researchers have demonstrated using ... was increased in stroke and traumatic brain injury ... rehabilitative treatment that helps these patients recover lost ... the peer-reviewed journal Neurorehabilitation and Neural Repair on ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... antiplatelet drugs (e.g., acetylsalicylic acid) are key therapeutic ... this study, Joseph Delaney MSc, Dr. James Brophy ... cases with a diagnosis of gastrointestinal bleeding and ... documented a 46-fold increase in the rate of ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 3Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Vision restoration therapy shown to improve brain activity in brain injured patients 2
Take Performance to a Higher Level....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Galaxy IVUS Imaging System simplifies the process of intracardiac echo while delivering accurate, real-time diagnostic information in less time with less work. (Ultra ICE catheter compatible)...
Medicine Products: